IP Library › Granted Patent US 10,568,848
Granted Patent B2
US 10,568,848 · App. 16/411,248 · Granted Feb 25, 2020

Treatment of autism with cannabidiol

Inventors: Terri Sebree (Gladwyne, PA); Marcel Bonn-Miller (Lexington, NC); Donna Gutterman (Raleigh, NC)
Assignee: ZYNERBA PHARMACEUTICALS, INC.
A61K31/05A61K9/0014A61K9/06A61K36/185A61P25/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,568,848
App. No.
16/411,248
Granted
Feb 25, 2020
Kind
B2
Abstract

The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.

Claims (9)

1. A method of treating a human suffering from an autism spectrum disorder comprising:

transdermally administering via a gel or cream a therapeutically effective amount of purified cannabidiol to the human suffering from the autism spectrum disorder to effectively treat the autism spectrum disorder in the human in need thereof.

2. The method of claim 1 , wherein the cannabidiol is (−)-cannabidiol.

3. The method of claim 1 , wherein the therapeutically effective amount of cannabidiol is 250 mg total daily.

4. The method of claim 1 , wherein the therapeutically effective amount of cannabidiol is 500 mg total daily.

5. The method of claim 1 , wherein the cannabidiol is formulated as a permeation-enhanced gel.

6. The method of claim 1 , wherein the cannabidiol is administered in a single-daily dose.

7. The method of claim 1 , wherein the cannabidiol is administered in two daily doses.

8. The method of claim 1 , wherein the therapeutically effective amount of cannabidiol is between about 50 mg to 500 mg total daily.

Assignments (2)
SUPPLEMENTAL CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded May 18, 2026
From: HARMONY BIOSCIENCES MANAGEMENT, INC. (F/K/A ZYNERBA PHARMACEUTICALS, INC.)
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 075642/0639 →
CONFIRMATORY ASSIGNMENT Recorded Oct 17, 2019
From: SEBREE, TERRI; BONN-MILLER, MARCEL; GUTTERMAN, DONNA
To: ZYNERBA PHARMACEUTICALS, INC.
Reel/Frame 050748/0699 →
Continuity (5)
Continuation 16220249 · Dec 14, 2018
Continuation 16144632 · Sep 27, 2018
Provisional Application 62632532 · Feb 20, 2018
Provisional Application 62564834 · Sep 28, 2017
Related Publication 20190262280A1 · Aug 29, 2019
Cited By (8)
US 12,186,280 US 12,186,282 US 12,213,951 US 12,226,373 US 12,268,699 US 12,409,131 US 12,409,132 US 12,714,718